9 Meters Biopharma Inc
Change company Symbol lookup
Select an option...
NMTR 9 Meters Biopharma Inc
LYLT Loyalty Ventures Inc
BOXD Boxed Inc
ALLR Allarity Therapeutics Inc
SIVB SVB Financial Group
NMRD Nemaura Medical Inc
LOGI Logitech International SA
BIOC Biocept Inc
KT KT Corp
SVRA Savara Inc
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs. Its pipeline includes Vurolenatide, Larazotide, NM-102, NM-003, NM-136 and NM-004. Vurolenatide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that combines exenatide with an extended half-life technology for treatment of short bowel syndrome (SBS). Larazotide is an 8-amino acid peptide formulated into an orally administered capsule for treatment of celiac disease. NM-102 is a small molecule peptide, is being developed as a potential microbiome modulator and is undergoing an indication selection process. NM-003 is a long-acting GLP-2 receptor agonist, for prevention of acute graft versus host disease. NM-004 is a double-cleaved mesalamine with an immunomodulator for pediatric ulcerative colitis.

Closing Price
$1.32
Day's Change
-0.06 (-4.35%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.43
Day's Low
1.29
Volume
(Light)
Volume:
68,308

10-day average volume:
93,213
68,308
Latest Earnings Beat Consensus (Q3 ending 09/2022)Next Earnings Announcement
Q3
Announced November 8, 2022
-$0.72Q3 Consensus
of 6 analysts
-$0.82Difference from
consensus
12.20%
Q4 Earnings
will announce
(Unconfirmed) May 15, 2023

Quarterly Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

NMTR's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.